New force in safety devices as Smiths Medical buys Medex
This article was originally published in Clinica
Smiths Medical has agreed to pay $925m for US firm Medex in a deal that will significantly strengthen its position in safety devices and anaesthesia products. The deal raises the profile of Smiths Medical in its sector by pushing its sales over the $1bn threshold, and was branded "the best opportunity that has come our way for many years" by the unit's managing director, Lawrence Kinet.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.